A new National Cancer Institute (NCI) funded clinical trial (TAILORx) has revealed that the use of Oncotype DX Breast Recurrence Score can help 70% of hormone receptor (HR) positive, HER2-negative, axillary lymph node-negative breast cancer patients to avoid chemotherapy and in turn its side-effects.
The score is a molecular test designed to analyse the expression of 21 genes associated with the cancer recurrence in order to determine the appropriate and effective post-operative treatment for women with this particular type of breast cancer.
